Lantern Pharma Announces Abstract on Effectiveness of LP-184 in Pancreatic Cancers Accepted for Presentation at the AACR Virtual Special Conference: Pancreatic Cancer
Lantern Pharma (LTRN) announced that its abstract, titled 'LP-184, a novel alkylating agent, is highly effective in pancreatic cancers with DNA damage repair defects', has been accepted for presentation at the AACR Virtual Special Conference on Pancreatic Cancer on September 29-30, 2021. The abstract highlights LP-184's promising efficacy in pancreatic cancer models, especially with DNA repair deficiencies. The drug has received Orphan Drug Designation from the FDA for pancreatic cancer treatment.
- LP-184 shows promising efficacy in preclinical pancreatic cancer models.
- LP-184 has received Orphan Drug Designation from the FDA.
- No FDA marketing approval for LP-184 yet.
- No guarantee of successful clinical testing or market introduction.
DALLAS, Aug. 16, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that Lantern Pharma's abstract titled 'LP-184, a novel alkylating agent, is highly effective in pancreatic cancers with DNA damage repair defects' has been accepted as a virtual poster at the upcoming AACR Virtual Special Conference on Pancreatic Cancer being held on September 29-30, 2021.
The abstract submitted by Lantern Pharma and researchers at Fox Chase Cancer Center describes work demonstrating promising efficacy of LP-184 in multiple in vitro and in vivo pancreatic cancer models. The abstract also highlights the increased efficacy and synthetic lethality of LP-184 in pancreatic cancers with DNA damage repair deficiencies.
Virtual posters will be available on-demand to attendees starting on September 29, 2021 and will remain accessible for 90 days after the live program ends. Accepted abstracts will be published as an online-only proceedings supplement to an AACR journal after the completion of the meeting.
LP-184 is a small molecule drug candidate and next generation alkylating agent that preferentially damages DNA in cancer cells that over-express certain biomarkers or that harbor mutations in DNA repair pathways. LP-184 is being developed for several targeted indications in cancer, including pancreatic cancer. LP-184 has recently been granted Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of pancreatic cancer.
About Lantern Pharma
Lantern Pharma (LTRN) is a clinical-stage oncology-focused biopharmaceutical company leveraging its proprietary RADR® A.I. platform and machine learning to discover biomarker signatures that identify patients most likely to respond to its pipeline of genomically-targeted therapeutics. Lantern is currently developing four drug candidates and an ADC program across eight disclosed tumor targets, including two phase 2 programs. By targeting drugs to patients whose genomic profile identifies them as having the highest probability of benefiting from the drug, Lantern's approach represents the potential to deliver best-in-class outcomes. More information is available at: www.lanternpharma.com and Twitter @lanternpharma.
Forward-looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages of our RADR® platform in identifying drug candidates and patient populations that are likely to respond to a drug candidate; our strategic plans to advance the development of our drug candidates and antibody drug conjugate (ADC) development program; estimates regarding the development timing for our drug candidates and ADC development program; our research and development efforts of our internal drug discovery programs and the utilization of our RADR® platform to streamline the drug development process; our intention to leverage artificial intelligence, machine learning and genomic data to streamline and transform the pace, risk and cost of oncology drug discovery and development and to identify patient populations that would likely respond to a drug candidate; estimates regarding potential markets and potential market sizes; sales estimates for our drug candidates and our plans to discover and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves or in collaboration with others. Any statements that are not statements of historical fact (including, without limitation, statements that use words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "objective," "aim," "should," "will," "would," or the negative of these words or other similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as (i) the impact of the COVID-19 pandemic, (ii) the risk that our research and the research of our collaborators in the area of pancreatic cancer may not be successful, (iii) the risk that none of our product candidates has received FDA marketing approval, and we may not be able to successfully initiate, conduct, or conclude clinical testing for or obtain marketing approval for our product candidates, (iv) the risk that no drug product based on our proprietary RADR A.I. platform has received FDA marketing approval or otherwise been incorporated into a commercial product, and (v) those other factors set forth in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Securities and Exchange Commission on March 10, 2021. You may access our Annual Report on Form 10-K for the year ended December 31, 2020 under the investor SEC filings tab of our website at www.lanternpharma.com or on the SEC's website at www.sec.gov. Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this press release represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations.
CONTACTS:
Investor Relations
David Waldman, Crescendo Communications, LLC
IR@lanternpharma.com
212-671-1021
Public Relations
Nicholas Koulermos, Vice President – 5W Public Relations
lantern@5wpr.com
646-843-1812
View original content to download multimedia:https://www.prnewswire.com/news-releases/lantern-pharma-announces-abstract-on-effectiveness-of-lp-184-in-pancreatic-cancers-accepted-for-presentation-at-the-aacr-virtual-special-conference-pancreatic-cancer-301355747.html
SOURCE Lantern Pharma
FAQ
What was announced by Lantern Pharma on August 16, 2021?
When is the AACR Virtual Special Conference taking place?
What is LP-184 and its significance?
What does Orphan Drug Designation mean for LP-184?
Has LP-184 received FDA approval?
